Johnson & Johnson filed a lawsuit in a New Jersey federal court, against Samsung Bioepis for breaching its contract agreement with the company over the launch of a biosimilar to its autoimmune drug ...

Following the successful Phase 2 trial of experimental lupus drug Stelara® (ustekinumab), researchers returned to the study data to uncover just how the treatment works. As previously reported, Phase ...

Credit: Fresenius Kabi. The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was highly similar to Stelara. Patients may now switch ...

Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has introduced a new presentation of Otulfi ® (ustekinumab ...

By Michael Erman and Mrinalika Roy Jan 21 (Reuters) - Johnson & Johnson on Wednesday forecast 2026 sales and profit ahead of ...

Sept. 26 -- FRIDAY, Sept. 25 (HealthDay News) -- Stelara (ustekinumab) has been approved by the U.S. Food and Drug Administration for adults with moderate-to-severe plaque psoriasis. The immune system ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. No significant differences were observed between Stelara ...

(Reuters) - Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment. The lawsuit, filed ...